Bauml JM, Mick R, Ciunci C, et al. - Through a phase 2 single-arm study that included 45 individuals with oligometastatic non–small cell lung cancer (NSCLC) who got pembrolizumab subsequent to completion of locally ablative therapy (LAT), experts assessed whether the addition of pembrolizumab following LAT enhanced outcomes for patients with oligometastatic NSCLC. Neither programmed death-ligand 1 expression nor CD8 T-cell tumor infiltration was related to progression-free survival (PFS) from the start of LAT. Pembrolizumab following LAT produced no new safety signals and no decrease in quality of life. Eleven patients expired. In conclusion, pembrolizumab following LAT for oligometastatic NSCLC seems to enhance PFS with no decrease in quality of life.